Toronto Dominion Bank
KNSA icon

Toronto Dominion Bank’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Toronto Dominion Bank’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$69 – 1696
2023
Q3 		$69 Hold
4
– – ﹤0.01% 1712
2023
Q2 		$0 Buy
+4
New +$54 ﹤0.01% 1650

Other funds holding KNSA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Toronto Dominion Bank's KNSA Position: Q4 2023 in Review

Toronto Dominion Bank sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2023, closing a stake of 4 shares — an estimated $69 sold.

Toronto Dominion Bank first reported a position in KNSA in Q2 2023 and held it in 2 quarters. The position peaked at $69 in Q3 2023. 142 funds tracked by Wall St. Rank hold KNSA as of Q4 2023.

  • Toronto Dominion Bank reported no remaining Kiniksa Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Toronto Dominion Bank sold 4 Kiniksa Pharmaceuticals shares in Q4 2023, an estimated $69.
  • Toronto Dominion Bank first reported a position in Kiniksa Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Toronto Dominion Bank's Kiniksa Pharmaceuticals position peaked at $69 in Q3 2023.
  • 142 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2023.

Based on Toronto Dominion Bank's 13F filing for Q4 2023, filed 13 Feb 2024.